Drug intelligence / Profile preview

AD-213-A

Development stage: Phase 1
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-213-A is a small molecule drug developed by Addpharma for the treatment of digestive system disorders, specifically targeting gastroesophageal reflux disease (GERD) and peptic esophagitis. It is classified as an antiulcer and gastric antisecretory agent, though its precise mechanism of action has not been defined in public sources. The drug has undergone Phase 1 clinical trials to evaluate its pharmacokinetics, pharmacodynamics, and safety profile in healthy adult subjects when administered orally. Development for reflux esophagitis was discontinued after Phase 1 trials[1][3][4].

Beyond the preview

Go deeper on AD-213-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-213-A.

Explore the full profile